Targeted radionuclide therapy for solid tumors: An overview

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  DeNardo, Sally J ^a   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CMRIT; MAb; RIT; Vascular leak

Indexed keywords

IMMUNOLOGY; MAGNETIC PROPERTIES; MEDICAL APPLICATIONS; MEDICAL IMAGING; POSITRON EMISSION TOMOGRAPHY; TUMORS;

COMBINED MODALITY THERAPY (CMRIT); MAB; RADIOIMMUNOTHERAPY (RIT); VASCULAR LEAK;

RADIOTHERAPY;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BIOTIN Y 90; CAPROMAB PENDETIDE IN 111; CAPROMAB PENDETIDE Y 90; FLUOROURACIL; LABETUZUMAB I 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33 I 131; MONOCLONAL ANTIBODY BRE3 Y 90; MONOCLONAL ANTIBODY CC49 I 131; MONOCLONAL ANTIBODY CHB72.3 I 131; MONOCLONAL ANTIBODY CHL6 I 131; MONOCLONAL ANTIBODY CHL6 Y 90; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY MN 14 I 131; MONOCLONAL ANTIBODY Y 90; NANOPARTICLE; PACLITAXEL; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; COLON CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; SOLID TUMOR; TREATMENT OUTCOME; TUMOR NECROSIS;

BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 33748443171     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.03.066     Document Type: Article

References (89)

1. Beierwaltes W.H. Radioiodine-labeled compounds previously or currently used for tumor localization. Panel Proceedings Series. In: Agency I.A.E. (Ed). Proceedings of an Advisory Group Meeting on Tumor Localization with Radioactive Agents (1974), International Atomic Energy Agency, Vienna, Austria 47-56
2. Order S.E., Stillwagon G.B., Klein J.L., et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 3 (1985) 1573-1582
3. DeNardo S.J., Erickson K.L., and Benjamini E. Use of I-131 antibodies for radiation therapy. [Abstract]. Clin Nucl Med 5 (1980) S4-S5
4. DeNardo S.J., Erickson K.L., Benjamini E., et al. Radioimmunotherapy for melanoma. [Abstract]. Clin Cancer Res 29 (1981) 434A
5. Carrasquillo J.A., Krohn K.A., Beaumier P., et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68 (1984) 317-328
6. Fisher B., Redmond C., Poisson R., et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320 (1989) 822-828
7. Lichter A.S., Lippman M.E., Danforth Jr. D.N., et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: A randomized trial at the National Cancer Institute. J Clin Oncol 10 (1992) 976-983
8. Sarrazin D., Le M.G., Arriagada R., et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14 (1989) 177-184
9. van Dongen J.A., Bartelink H., Fentiman I.S., et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst 11 (1992) 15-18
10. Howell L.P., DeNardo S.J., Levy N., et al. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. Int J Biol Markers 10 (1995) 126-135
11. Marken J.S., Schieven G.L., Hellstrom I., et al. Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci USA 89 (1992) 3503-3507
12. DeNardo S.J., Mirick G.R., Kroger L.A., et al. The biologic window for chimeric L6 radioimmunotherapy. Cancer 73 Suppl (1994) 1023-1032
13. DeNardo S.J., O'Grady L.F., Richman C.M., et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 17 (1997) 1745-1752
14. DeNardo S.J. Radioimmunotherapy in the treatment of metastatic breast cancer: An overview. In: Goldenberg D.M. (Ed). Cancer therapy with radiolabeled antibodies (1995), CRC Press, Inc, Ann Arbor, MI 189-201
15. Richman C.M., Schuermann T.C., Wun T., et al. Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma. Cancer 80 (1997) 2728-2732
16. Gold P., and Freedman S.O. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122 (1965) 467-481
17. Esteban J.M., Felder B., Ahn C., et al. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 74 (1994) 1575-1583
18. Goldenberg D.M. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J Clin 44 (1994) 43-64
19. Nabi H.A. Antibody imaging in breast cancer. Semin Nuclear Med 27 (1997) 30-39
20. 90Y)-chimeric T84.66 (cT84.66) anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer. [Abstract]. Cancer Biother Radiopharm 13 (1998) 314
21. Wagener C., Yang H.J., Crawford F.G., et al. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: A systematic approach for the determination of epitope specificities of monoclonal antibodies. J Immunol 130 (1983) 2308-2315
22. 99mTc SM3 radioimmunoscintigraphy. Acta Oncol 35 (1996) 319-321
23. Kramer E.L., DeNardo S.J., Liebes L., et al. Radioimmunolocalization of breast carcinoma using BrE-3 monoclonal antibody: Phase I study. J Nucl Med 34 (1993) 1067-1074
24. Baum R.P., and Brummendorf T.H. Radioimmunolocalization of primary and metastatic breast cancer. Q J Nucl Med 42 (1998) 33-42
25. Major P.P., Dion A.S., Williams C.J., et al. Breast tumor radioimmunodetection with a 111-In-labeled monoclonal antibody (MA5) against a mucin-like antigen. Cancer Res 50 (1990) 927s-931s
26. Buckman R., De Angelis C., Shaw P., et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 47 (1992) 102-109
27. DeNardo S.J., Kramer E.L., O'Donnell R.T., et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 38 (1997) 1180-1185
28. 111In. Nucl Med Commun 13 (1992) 11-19
29. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res 55 (1995) 5921s-5924s
30. Cagnoni P.J., Ceriani R.L., Cole W.C., et al. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer. [Abstract]. Cancer Biother Radiopharm 13 (1998) 328
31. Kramer E.L., Liebes L., Wasserheit C., et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 4 (1998) 1679-1688
32. 90Y DOTA-Lym-1 and m170 MAbs in clinical trials. [Abstract]. J Nucl Med 43 (2002) 117P
33. DeNardo S.J. Radioimmunotherapy for breast cancer: Systemic tumor-targeted irradiation. Adv Oncol 15 (1999) 23-29
34. 90Y monoclonal antibodies 170H. 82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 5 (1999) 3243s-3248s
35. 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol 38 (2001) 25-35
36. Gonzalez Trotter D.E., Manjeshwar R.M., Doss M., et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 45 (2004) 1237-1244
37. Kotts C.E., Su F.M., Leddy C., et al. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: Comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother Radiopharm 11 (1996) 133-144
38. Schlom J., Siler K., Milenic D.E., et al. Monoclonal antibody-based therapy of a human tumor xenograft with a 177-lutetium-labeled immunoconjugate. Cancer Res 51 (1991) 2889-2896
39. Goldenberg D.M., DeLand F.H., Bennett S.J., et al. Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. [Abstract]. JAMA 250 (1983) 630-635
40. Meredith R.F., Bueschen A.J., Khazaeli M.B., et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 35 (1994) 1017-1022
41. Meredith R.F., Khazaeli M.B., Macey D.J., et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 5 (1999) 3254s-3258s
42. Deb N., Goris M., Trisler K., et al. Treatment of hormone-refractory prostate cancer with 90-Y-CYT-356 monoclonal antibody. Clin Cancer Res 2 (1996) 1289-1297
43. Kahn D., Austin J.C., Maguire R.T., et al. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following a radical prostatectomy. [Abstract]. Cancer Biother Radiopharm 14 (1999) 99-111
44. Gong M.C., Chang S.S., Sadelain M., et al. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev 18 (1999) 483-490
45. Gong M.C., Chang S.S., Watt F., et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. [Abstract]. Molec Urol 4 (2000) 217-222
46. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 60 (2000) 6095-6100
47. DeNardo S.J., Richman C.M., Albrecht H., et al. Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res 11 (2005) 7187s-7194s
48. 90Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res 7 (2001) 1561-1568
49. Richman C.M., DeNardo S.J., O'Donnell R.T., et al. High-dose radioimmunotherapy combined with fixed, low-dose Paclitaxel in metastatic prostate and breast cancer using a MUC-1 monoclonal antibody, M170, linked to Indium-111/Yttrium-90 via a cathepsin B cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 11 (2005) 5920-5927
50. Behr T.M., Sharkey R.M., Juweid M., et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin antibodies. [Abstract]. J Nucl Med 38 (1997) 409-418
51. Murray J.L. Radioimmunotherapy of colorectal cancer. In: Goldenberg D.M. (Ed). Cancer therapy with radiolabeled antibodies (1995), CRC Press, Boca Raton, FL 173-187
52. Heath J.K., White S.J., Johnstone C.N., et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. [Abstract]. Proc Natl Acad Sci USA 94 (1997) 469-474
53. Welt S., Divgi C.R., Kemeny N., et al. Phase I/II study of iodine-131 labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12 (1994) 1561-1571
54. Knox S.J., Goris M.L., Tempero M., et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6 (2000) 406-414
55. Behr T.M., Liersch T., Greiner-Bechert L., et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94 (2002) 1373-1381
56. Buchegger F., Allal A.S., Roth A., et al. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer; a feasibility study. Anticancer Res 20 (2000) 1889-1996
57. DeNardo G.L., O'Donnell R.T., Kroger L.A., et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res 10 (1999) 3219-3223
58. 90Yttrium-DOTA-peptide-ChL6. Prostate 50 (2002) 27-37
59. Clarke K., Lee F.T., Brechbiel M.W., et al. Therapeutic efficacy of anti-Lewis (y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with Taxol chemotherapy. Clin Cancer Res 6 (2000) 3621-3628
60. van Gog F.B., Brakenhoff R.H., Stigter-van Walsum M., et al. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 77 (1998) 13-18
61. Bianco C., Bianco R., Tortora G., et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6 (2000) 4343-4350
62. 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm 13 (1998) 351-361
63. Buchsbaum D.J. Experimental radioimmunotherapy. Semin Radiat Oncol 10 (2000) 156-167
64. DeNardo S.J., Richman C.M., Kukis D.L., et al. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocol. Anticancer Res 18 (1998) 4011-4018
65. DeNardo S.J., Kroger L.A., Lamborn K.R., et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 80 Suppl (1997) 2583-2590
66. Burke P.A., DeNardo S.J., Miers L.A., et al. Combined modality radioimmunotherapy: Promise and peril. Clin Cancer Res 94 (2002) 1320-1331
67. Winthrop M.D., DeNardo S.J., Muenzer J.T., et al. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer 80 Suppl (1997) 2529-2537
68. DeNardo S.J., Kukis D.L., Miers L.A., et al. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 39 (1998) 842-849
69. DeNardo S.J., Kukis D.L., Kroger L.A., et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 94 (1997) 4000-4004
70. Crow D.M., Williams L., Colcher D., et al. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with Taxol. Bioconjug Chem 16 (2005) 1117-1125
71. Meredith R.F., Alvarez R.D., Partridge E.E., et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 16 (2001) 305-315
72. Liersch T., Meller J., Kulle B., et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-Labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol 23 (2005) 6763-6764
73. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285 (1971) 1182-1186
74. Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
75. Brooks P.C., Montgomery A.M., Rosenfeld M., et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
76. Castronovo V., and Belotti D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 32A (1996) 2520-2527
77. Nguyen M., Tran C., Barsky S., et al. Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies. Int J Oncol 10 (1997) 965-969
78. Klohs W.D., and Hamby J.M. Antiangiogenic agents. Curr Opin Biotechnol 10 (1999) 544-549
79. Molema G., and Griffioen A.W. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today 19 (1998) 392-394
80. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-R24
81. Lund E.L., Bastholm L., and Kristjansen P.E.G. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6 (2000) 971-978
82. Gorski D.H., Mauceri H.J., Salloum R.M., et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58 (1998) 5686-5689
83. DeNardo S.J., Burke P.A., Leigh B.R., et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm 15 (2000) 71-79
84. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62 (2002) 4263-4272
85. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54 (2002) 531-545
86. Nobs L., Buchegger F., Gurny R., et al. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 17 (2005) 139-145
87. Gourley P.L. Brief overview of BioMicroNano technologies. Biotechnol Prog 2 (2005) 2-10
88. Broz P., Benito S.M., Saw C., et al. Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J Control Release 102 (2005) 475-488
89. DeNardo S.J., DeNardo G.L., Miers L.A., et al. Development of tumor targeting bioprobes (111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 11 (2005) 7087s-7092s